Journal article
Long-term benefits of intensive glucose Control for preventing end-stage kidney disease: ADVANCE-ON
MG Wong, V Perkovic, J Chalmers, M Woodward, Q Li, ME Cooper, P Hamet, S Harrap, S Heller, S Macmahon, G Mancia, M Marre, D Matthews, B Neal, N Poulter, A Rodgers, B Williams, S Zoungas
Diabetes Care | Published : 2016
DOI: 10.2337/dc15-2322
Abstract
OBJECTIVE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes. RESEARCH DESIGN AND METHODS: Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baselin..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
The ADVANCE trial and ADVANCE-ON follow-up study were funded by unrestricted grants from Servier and the Australia National Health and Medical Research Council. M.G.W. reports fees for scientific lectures from AstraZeneca. V.P. reports honoraria for scientific lectures from Boehringer Ingelheim, Merck, AbbVie, Roche, AstraZeneca, and Servier and serves on steering committees and/or advisory boards supported by AbbVie, Astellas, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, and Pfizer. J.C. reports research grants administered through the University of Sydney for the ADVANCE trial and the ADVANCE-ON post-trial study and honoraria from Servier for speaking about these studies at scientific meetings. P.H. is a member of College International de Recherche Servier. B.W. has received honoraria from Servier for lectures at scientific meetings. S.Z. reports past participation in advisory boards and/or receiving honoraria from Amgen Australia, AstraZeneca/Bristol-Myers Squibb Australia, Janssen-Cilag, Merck Sharp & Dohme (Australia), Novartis Australia, Sanofi, Servier Laboratories, and Takeda Australia as well as Monash University undertaking contract work for AstraZeneca Pty Ltd./Bristol-Myers Squibb Australia Pty Ltd. No other potential conflicts of interest relevant to this article were reported.